This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2010 Jul;58(1):8-9.

doi: 10.1016/j.eururo.2010.03.030. Epub 2010 Mar 26.

Defining and treating high-risk prostate cancer: can we do better?

Leah Gerber, Lionel L Bañez, Stephen J Freedland

PMID: 20363552
DOI: 10.1016/j.eururo.2010.03.030

Editorial

Defining and treating high-risk prostate cancer: can we do better?

Leah Gerber et al. Eur Urol. 2010 Jul.

. 2010 Jul;58(1):8-9.

doi: 10.1016/j.eururo.2010.03.030. Epub 2010 Mar 26.

Authors

Leah Gerber, Lionel L Bañez, Stephen J Freedland

PMID: 20363552
DOI: 10.1016/j.eururo.2010.03.030

No abstract available

PubMed Disclaimer

Comment on

Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients.
Spahn M, Joniau S, Gontero P, Fieuws S, Marchioro G, Tombal B, Kneitz B, Hsu CY, Van Der Eeckt K, Bader P, Frohneberg D, Tizzani A, Van Poppel H. Spahn M, et al. Eur Urol. 2010 Jul;58(1):1-7; discussion 10-1. doi: 10.1016/j.eururo.2010.03.001. Epub 2010 Mar 17. Eur Urol. 2010. PMID: 20299147

Similar articles

Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer.
D'Amico AV, Chen MH. D'Amico AV, et al. J Clin Oncol. 2009 Aug 1;27(22):3575-6. doi: 10.1200/JCO.2009.22.6068. Epub 2009 Jun 8. J Clin Oncol. 2009. PMID: 19506151 No abstract available.
Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
Rosser CJ, Parker A. Rosser CJ, et al. J Urol. 2005 Sep;174(3):1154-5; author reply 1155-6. doi: 10.1097/01.ju.0000169211.49050.8f. J Urol. 2005. PMID: 16094093 No abstract available.
Re: Zhao et al.: External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment Score (Urology 2008;72:396-400).
Stephenson AJ. Stephenson AJ. Urology. 2008 Sep;72(3):719-20. doi: 10.1016/j.urology.2008.01.039. Urology. 2008. PMID: 18762055 No abstract available.
[Prognosis and predictive factors in prostate cancer].
Albiges-Sauvin L, Lévy A, Massard C, Fizazi K. Albiges-Sauvin L, et al. Bull Cancer. 2009 Apr;96(4):439-49. doi: 10.1684/bdc.2009.0846. Bull Cancer. 2009. PMID: 19357018 Review. French.
The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer.
Pannek J, Partin AW. Pannek J, et al. Semin Urol Oncol. 1998 Aug;16(3):100-5. Semin Urol Oncol. 1998. PMID: 9741413 Review.

See all similar articles

Cited by

Radical prostatectomy and intraoperative radiation therapy in high-risk prostate cancer.
Marchioro G, Volpe A, Tarabuzzi R, Apicella G, Krengli M, Terrone C. Marchioro G, et al. Adv Urol. 2012;2012:687230. doi: 10.1155/2012/687230. Epub 2012 Jan 30. Adv Urol. 2012. PMID: 22400019 Free PMC article.
Utilizing mRNA extracted from small, archival formalin-fixed paraffin-embedded prostate samples for translational research: assessment of the effect of increasing sample age and storage temperature.
Stewart GD, Baird J, Rae F, Nanda J, Riddick AC, Harrison DJ. Stewart GD, et al. Int Urol Nephrol. 2011 Dec;43(4):961-7. doi: 10.1007/s11255-011-9948-3. Epub 2011 Mar 30. Int Urol Nephrol. 2011. PMID: 21448682

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information